Pfizer Inc. PFE on Tuesday reported better-than-expected first-quarter results and reaffirmed its 2026 financial guidance. This positive momentum comes alongside a broader market environment where S&P ...

BridgeBio (BBIO) says heart disease therapy Attruby beat Pfizer’s (PFE) rival drug, tafamidis, branded as Vyndamax, in a real ...

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return ...

The Vyndamax franchise, which includes Vyndaqel, has attracted scrutiny for its high high prices. Now, Pfizer says a proposed generic steps on its patent. (Pfizer) Just four years into the rollout of ...

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S. District Court for the District of Delaware. Vyndamax remains the market leader ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer (NYSE: PFE) recently reached settlements with three generic drugmakers -- Hikma, Cipla, and Dexcel -- to extend the patent protection of Vyndamax, one of its best-selling drugs, through June ...

Pfizer has reached legal settlements with three drug manufacturers related to alleged patent infringement for its Vyndamax drug. The biopharmaceutical company said Tuesday that it settled with Dexcel ...

My husband has been diagnosed with cardiac amyloidosis. The doctor has started him on Vyndamax, a very expensive drug. Without this drug, he is lucky to live, at the most, two years. Is this drug a ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...